Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment

Research output: Contribution to journalJournal articlepeer-review

Harvard

Espelund, U, Grønbaek, H, Villadsen, GE, Simonsen, K, Vestergaard, PF, Jørgensen, JOL, Flyvbjerg, A, Vilstrup, H & Frystyk, J 2015, 'The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment', Growth Hormone & IGF Research, vol. 25, no. 4, pp. 174-81. https://doi.org/10.1016/j.ghir.2015.05.002

APA

Espelund, U., Grønbaek, H., Villadsen, G. E., Simonsen, K., Vestergaard, P. F., Jørgensen, J. O. L., Flyvbjerg, A., Vilstrup, H., & Frystyk, J. (2015). The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. Growth Hormone & IGF Research, 25(4), 174-81. https://doi.org/10.1016/j.ghir.2015.05.002

CBE

Espelund U, Grønbaek H, Villadsen GE, Simonsen K, Vestergaard PF, Jørgensen JOL, Flyvbjerg A, Vilstrup H, Frystyk J. 2015. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. Growth Hormone & IGF Research. 25(4):174-81. https://doi.org/10.1016/j.ghir.2015.05.002

MLA

Vancouver

Espelund U, Grønbaek H, Villadsen GE, Simonsen K, Vestergaard PF, Jørgensen JOL et al. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. Growth Hormone & IGF Research. 2015 Aug;25(4):174-81. https://doi.org/10.1016/j.ghir.2015.05.002

Author

Espelund, Ulrick ; Grønbaek, Henning ; Villadsen, Gerda Elisabeth ; Simonsen, Kira ; Vestergaard, Poul Frølund ; Jørgensen, Jens Otto Lunde ; Flyvbjerg, Allan ; Vilstrup, Hendrik ; Frystyk, Jan. / The Circulating IGF System in Hepatocellular Carcinoma : The Impact of Liver Status and Treatment. In: Growth Hormone & IGF Research. 2015 ; Vol. 25, No. 4. pp. 174-81.

Bibtex

@article{2b19e7e400164c6a93e12d9dda61495a,
title = "The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment",
abstract = "BACKGROUND: Previous studies have demonstrated an elevated IGF-II mRNA expression and protein levels in tumors and blood from patients with hepatocellular carcinoma (HCC), hereby suggesting a role of IGF-II as a pathogenic marker of HCC. We hypothesized that in HCC, an increased IGF-II secretion would translate into an elevated circulating IGF bioactivity, which would normalize following treatment.METHODS: Patients with HCC (n=39) were studied before and after radio-frequency ablation and/or transarterial chemo-embolization. Baseline data were compared to healthy subjects (n=150) and patients with liver cirrhosis (n=41). Serum levels of IGF ligands and IGF binding proteins (IGFBPs) were determined using gold standard methods as well as novel assays and compared to liver function tests and HCC treatment status.RESULTS: At baseline, HCC patients differed from cirrhosis patients and healthy controls regarding IGF-I (29 [23-37] vs. 12 [7-19] vs. 109 [103-116] μg/l), IGF-II (254 [224-288] vs. 118 [102-137] vs. 545 [525-566] μg/l) and IGF bioactivity (0.53 [0.41-0.68] vs. 0.29 [0.24-0.34] vs. 1.43 [1.33-1.53] μg/l) (mean [95% confidence interval], all age-adjusted P<0.001). All variables but IGFBP-2 were strongly associated with liver status (MELD score), and accordingly, differences were either attenuated or disappeared when adjusted for MELD score. There was no effect of treatment on any IGF variables.CONCLUSIONS: The marked differences in IGF and IGFBP levels between patients with HCC, liver cirrhosis and healthy subjects are mainly explained by variations in liver status. Therefore, this study questions the clinical utility of circulating IGF variables as markers of HCC.",
keywords = "Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Hepatocellular, Case-Control Studies, Female, Humans, Insulin-Like Growth Factor Binding Protein 2, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Protein Precursors, Young Adult, Journal Article, Research Support, Non-U.S. Gov't",
author = "Ulrick Espelund and Henning Gr{\o}nbaek and Villadsen, {Gerda Elisabeth} and Kira Simonsen and Vestergaard, {Poul Fr{\o}lund} and J{\o}rgensen, {Jens Otto Lunde} and Allan Flyvbjerg and Hendrik Vilstrup and Jan Frystyk",
note = "Copyright {\textcopyright} 2015 Elsevier Ltd. All rights reserved.",
year = "2015",
month = aug,
doi = "10.1016/j.ghir.2015.05.002",
language = "English",
volume = "25",
pages = "174--81",
journal = "Growth Hormone & I G F Research",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "4",

}

RIS

TY - JOUR

T1 - The Circulating IGF System in Hepatocellular Carcinoma

T2 - The Impact of Liver Status and Treatment

AU - Espelund, Ulrick

AU - Grønbaek, Henning

AU - Villadsen, Gerda Elisabeth

AU - Simonsen, Kira

AU - Vestergaard, Poul Frølund

AU - Jørgensen, Jens Otto Lunde

AU - Flyvbjerg, Allan

AU - Vilstrup, Hendrik

AU - Frystyk, Jan

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/8

Y1 - 2015/8

N2 - BACKGROUND: Previous studies have demonstrated an elevated IGF-II mRNA expression and protein levels in tumors and blood from patients with hepatocellular carcinoma (HCC), hereby suggesting a role of IGF-II as a pathogenic marker of HCC. We hypothesized that in HCC, an increased IGF-II secretion would translate into an elevated circulating IGF bioactivity, which would normalize following treatment.METHODS: Patients with HCC (n=39) were studied before and after radio-frequency ablation and/or transarterial chemo-embolization. Baseline data were compared to healthy subjects (n=150) and patients with liver cirrhosis (n=41). Serum levels of IGF ligands and IGF binding proteins (IGFBPs) were determined using gold standard methods as well as novel assays and compared to liver function tests and HCC treatment status.RESULTS: At baseline, HCC patients differed from cirrhosis patients and healthy controls regarding IGF-I (29 [23-37] vs. 12 [7-19] vs. 109 [103-116] μg/l), IGF-II (254 [224-288] vs. 118 [102-137] vs. 545 [525-566] μg/l) and IGF bioactivity (0.53 [0.41-0.68] vs. 0.29 [0.24-0.34] vs. 1.43 [1.33-1.53] μg/l) (mean [95% confidence interval], all age-adjusted P<0.001). All variables but IGFBP-2 were strongly associated with liver status (MELD score), and accordingly, differences were either attenuated or disappeared when adjusted for MELD score. There was no effect of treatment on any IGF variables.CONCLUSIONS: The marked differences in IGF and IGFBP levels between patients with HCC, liver cirrhosis and healthy subjects are mainly explained by variations in liver status. Therefore, this study questions the clinical utility of circulating IGF variables as markers of HCC.

AB - BACKGROUND: Previous studies have demonstrated an elevated IGF-II mRNA expression and protein levels in tumors and blood from patients with hepatocellular carcinoma (HCC), hereby suggesting a role of IGF-II as a pathogenic marker of HCC. We hypothesized that in HCC, an increased IGF-II secretion would translate into an elevated circulating IGF bioactivity, which would normalize following treatment.METHODS: Patients with HCC (n=39) were studied before and after radio-frequency ablation and/or transarterial chemo-embolization. Baseline data were compared to healthy subjects (n=150) and patients with liver cirrhosis (n=41). Serum levels of IGF ligands and IGF binding proteins (IGFBPs) were determined using gold standard methods as well as novel assays and compared to liver function tests and HCC treatment status.RESULTS: At baseline, HCC patients differed from cirrhosis patients and healthy controls regarding IGF-I (29 [23-37] vs. 12 [7-19] vs. 109 [103-116] μg/l), IGF-II (254 [224-288] vs. 118 [102-137] vs. 545 [525-566] μg/l) and IGF bioactivity (0.53 [0.41-0.68] vs. 0.29 [0.24-0.34] vs. 1.43 [1.33-1.53] μg/l) (mean [95% confidence interval], all age-adjusted P<0.001). All variables but IGFBP-2 were strongly associated with liver status (MELD score), and accordingly, differences were either attenuated or disappeared when adjusted for MELD score. There was no effect of treatment on any IGF variables.CONCLUSIONS: The marked differences in IGF and IGFBP levels between patients with HCC, liver cirrhosis and healthy subjects are mainly explained by variations in liver status. Therefore, this study questions the clinical utility of circulating IGF variables as markers of HCC.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers, Tumor

KW - Carcinoma, Hepatocellular

KW - Case-Control Studies

KW - Female

KW - Humans

KW - Insulin-Like Growth Factor Binding Protein 2

KW - Insulin-Like Growth Factor Binding Protein 3

KW - Insulin-Like Growth Factor I

KW - Insulin-Like Growth Factor II

KW - Liver Cirrhosis

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Protein Precursors

KW - Young Adult

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.ghir.2015.05.002

DO - 10.1016/j.ghir.2015.05.002

M3 - Journal article

C2 - 26068014

VL - 25

SP - 174

EP - 181

JO - Growth Hormone & I G F Research

JF - Growth Hormone & I G F Research

SN - 1096-6374

IS - 4

ER -

ID: 51690382